How Many People Take GLP-1: A Deep Dive into Usage Trends and Insights

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Approximately 9 million Americans are currently taking GLP-1 medications, representing a dramatic shift in how metabolic health is managed. This surge reflects growing clinical evidence and real-world success across diverse populations. PlexusDx helps individuals access personalized GLP-1 therapy without insurance requirements or membership fees.

Global GLP-1 Adoption and Market Growth

GLP-1 receptor agonist prescriptions have increased by over 1,200% in major markets since 2021. This expansion extends beyond diabetes management into weight loss and metabolic optimization. Compounded versions, manufactured in licensed 503A pharmacies, have democratized access by reducing barriers to entry and offering affordability comparable to specialty medications.

Market research indicates that GLP-1 users span all income levels, ages 25–75, and across urban and rural regions. Insurance limitations and prior authorization delays historically restricted access, but direct-to-consumer platforms like PlexusDx have shifted this landscape. Today, individuals can initiate treatment within days rather than weeks or months.

Demographics of GLP-1 Users

Women comprise roughly 60–65% of GLP-1 users, driven by higher obesity prevalence and greater engagement with preventive health strategies. Age distribution peaks between 35–55 years, though increasing numbers of individuals in their 60s and 70s are benefiting from these medications. Metabolic conditions like type 2 diabetes, prediabetes, and obesity-related cardiovascular risk drive most prescriptions.

Socioeconomic diversity has increased as compounded semaglutide and tirzepatide become accessible outside traditional insurance networks. Geographic adoption shows stronger penetration in urban centers, yet rural adoption is accelerating through telehealth platforms. PlexusDx serves all 50 states, ensuring equitable access regardless of location or insurance status.

Why GLP-1 Usage Continues to Rise

Clinical evidence demonstrates that GLP-1 agonists produce sustained weight loss of 15–22% of body weight over 68 weeks, significantly outperforming older weight management approaches. Beyond weight reduction, these medications improve blood sugar control, reduce cardiovascular event risk, and lower inflammatory markers. Real-world testimonials and social proof have accelerated interest among individuals previously skeptical of medication-based interventions.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Personalized GLP-1 Therapy and Genetic Insights

Not all GLP-1 users respond identically due to genetic variation in receptor sensitivity, hunger regulation, and glucose metabolism. Key genetic variants—including GIPR rs1800437 and FTO rs9939609—influence baseline appetite set-point and drug responsiveness. The Precision Peptide Genetic Test identifies which of 14 metabolic pathways most strongly regulate your weight and appetite, enabling truly personalized dosing strategies.

PlexusDx integrates genetic insights with clinical monitoring to optimize outcomes. Compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan, with dosing flexibility that grows with your physiology—not your budget. Oral and injectable tirzepatide options, plus dual-compound GLP-Squared formulations, provide alternatives for patients with specific preferences or absorption considerations. The $298 Precision Peptide Genetic Test becomes available after your first treatment month, ensuring your therapy aligns with your metabolic blueprint.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How many people are currently using GLP-1 medications in the United States?

Approximately 9 million Americans are taking GLP-1 medications for weight management, metabolic health, or diabetes control. This number has grown from roughly 600,000 in 2021, reflecting increased clinical confidence and expanded access through direct-to-consumer platforms.

What percentage of GLP-1 users are taking these drugs for weight loss versus diabetes?

Approximately 70–75% of current GLP-1 users take these medications primarily for weight management, while 25–30% address diabetes or prediabetes. This shift reflects growing recognition of GLP-1 agonists as effective weight loss tools independent of diabetes status. PlexusDx supports both populations with flexible dosing and pricing structures.

Are compounded GLP-1 medications from PlexusDx as safe as brand-name versions?

Compounded semaglutide and tirzepatide from licensed 503A pharmacies contain identical active pharmaceutical ingredients manufactured to the same standards as brand medications. The key difference is cost and accessibility—PlexusDx compounded versions are $189/mo month-to-month, or from $149/mo on the 6-month plan for semaglutide injection, making them accessible without insurance.

How does the Precision Peptide Genetic Test improve GLP-1 outcomes?

No — the Precision Peptide Genetic Test does not predict your response to GLP-1 medications or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I use HSA or FSA funds to pay for PlexusDx GLP-1 medications?

Yes, all PlexusDx GLP-1 medications are HSA- and FSA-eligible, making them accessible to individuals using tax-advantaged health savings accounts. Combined with starting prices of $149/month for semaglutide injection, this option maximizes affordability.

Related Reading

• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.